Hvordan 4-Pro-MET blev opdaget historie

How 4-Pro-MET Was Discovered

From Shulgin's 4-HO-MET to the Emergence of a Novel Prodrug Tryptamine

4-Pro-MET dukkede første gang op på det europæiske research-chemical-marked i august/september 2025. Hvorfra kommer denne substans? Hvem syntetiserede den først, og hvorfor netop nu? Historien om 4-Pro-MET er simultant historien om prodrug-kemi, tryptaminsystematik og et voksende marked for legale forskningskemikalier. Fra Shulgins grundlag til det kommercielle research chemical.

Indholdsfortegnelse

Indlæser...

Shulgins fundament: 4-HO-MET

4-Pro-MET eksisterer kun på grund af én substans: 4-HO-MET (Metocin), syntetiseret af Alexander Shulgin i 1970'erne i hans privatlaboratorium i Californien. Dokumenteret i TiHKAL (1997) som indgang #21:

Syntese: Tofaset fra 4-acetoxyindol – oxalylchlorid – methylethylamin – LiAlH4-reduktion
Dosis: 10–20 mg oralt
Varighed: 4–6 timer
Shulgins kommentar: 'Qualitatively a lot like psilocin. I started within the first half-hour, and at the max, I felt the same alteration of color and form'

Shulgin varierede systematisk N-substitutionen (methyl, ethyl, propyl, isopropyl) og position-4-modifikationen (hydroxy, acetyloxy, phosphoryloxy). Snesevis af variationer over grundstrukturen. Propionyloxy-varianten (4-Pro-MET) mangler i TiHKAL – den blev tilsyneladende ikke syntetiseret eller dokumenteret i Shulgins levetid.

Logikken bag 4-Pro-MET blev allerede demonstreret ved psilocybin: Den frie 4-hydroxylgruppe ved tryptaminer som 4-HO-MET og psilocin er kemisk ustabil – oxiderer i luft og nedbrydes. Løsningen: En beskyttelsesgruppe, der fjernes enzymatisk i organismen. Tre strategier er etablerede:

Phosphoryloxy (PO): Psilocybin-strategi. Meget stabil, men syntetisk krævende. Spaltning via phosphataser.
Acetyloxy (AcO): 4-AcO-DMT/4-AcO-MET-strategi. Enkel at syntetisere, god stabilitet. Spaltning via esteraser. Tilgængelig som RC siden ~2010.
Propionyloxy (PrO): 4-Pro-MET/4-PrO-DMT-strategi. Højere stabilitet end AcO (længere kæde = mere sterisk afskærmning), langsommere hydrolyse.

Propionyloxy er den logiske videreudvikling af acetyloxy: Et yderligere CH2-led i esterkæden øger lagerstabiliteten (anslået 2–3 vs. 1–2 år) og forsinker onset. Lipinskis regler: +0,5 logP-enheder pr. CH? – højere lipofili – bedre membranpermeabilitet – langsommere renal clearance – længere virkningsvarighed.

Ester prodrugs of 4-hydroxy tryptamines go back to the 1960s, with psilocybin itself as the natural prototype (phosphoryloxy ester). The synthetic acetyloxy (4-AcO) series – including 4-AcO-DMT and 4-AcO-MET – gained popularity in the 2000s-2010s for their improved stability over free-hydroxyl compounds. When 4-AcO-DMT was added to BtMG Anlage I in Germany in 2022, pressure to develop alternative ester variants intensified.

The propionyloxy (4-PrO) series is the next logical step: extending the acyl chain from two carbons (acetyloxy) to three carbons (propionyloxy). This provides marginally increased stability, slightly slower hydrolysis (potentially smoothing onset), and – critically – a different structure that falls outside existing scheduling definitions. 4-Pro-MET first appeared in vendor catalogs in August/September 2025, quickly gaining attention as a legal, stable prodrug of 4-HO-MET.

Fremkomsten af 4-Pro-MET i august/september 2025 er ingen tilfeldighed. Flere tendenser konvergerede:

1. Regulatorisk pres

Da 4-HO-MET i visse jurisdiktioner kom på regulerede lister, opstod der efterspørgsel efter legale alternativer. Prodrugs af regulerede substanser tilbyder et 'juridisk stødpude' – selv ikke opført, selvom metabolitten er det. Mønsteret kendes fra LSD: Efter forbuddet mod 1P-LSD kom 1cP-LSD, derefter 1D-LSD, så 1T-LSD.

2. Videnskabeligt grundlag

Glatfelter et al. (2023) tilvejebragte første gang systematiske data om propionyloxytryptaminer og viste, at strategien farmakologisk fungerer. Det opmuntrede synteselaboratorier til også at fremstille MET-varianten.

3. Stabilitetsfordel

4-Pro-MET tilbyder over for 4-AcO-MET en praktisk fordel: højere lagerstabilitet (2–3 vs. 1–2 år). Længere holdbarhed, færre nedbrydningstab, pålideligere produkter.

4-Pro-MET was first registered as a novel designer drug in August/September 2025. Its rapid adoption reflected several converging factors: the scheduling of 4-AcO-DMT (2022), NpSG coverage of 4-HO-MET (2019), strong community demand for MET-series compounds, and proven commercial viability of the prodrug tryptamine market. Within months, multiple European vendors were offering 4-Pro-MET in pellet and drop formats, with Certificates of Analysis confirming identity and purity.

The compound's molecular formula (C₁₆H₂₂N₂O₂, MW 274.364 g/mol) and its availability as a fumarate salt for stability were quickly documented. PubChem assigned CID 169222171. No academic publications addressing 4-Pro-MET have appeared as of April 2026, making community reports and structural analogy the only information sources available.

Juridisk meddelelse

Dies ist ein Beispiel-Infotext. Hier können Sie wichtige Hinweise für Ihre Leser hinterlegen.

Lab-Tested 4-Pro-MET

Quality-verified – CoA included – EU shipping

Se produkter

Frequently Asked Questions

Who invented 4-Pro-MET?

The specific originator is unknown. 4-Pro-MET applies established ester prodrug chemistry to Alexander Shulgin's 4-HO-MET. It likely originated from a research chemical laboratory responding to market demand for a legal, stable alternative after scheduling of 4-HO-MET and 4-AcO-DMT.

When did 4-Pro-MET first appear?

4-Pro-MET was first registered as a novel designer drug in August/September 2025. Multiple European vendors began offering it in pellet and drop formats within months of its emergence. No academic publications specific to 4-Pro-MET exist as of April 2026.

Is 4-Pro-MET mentioned in TiHKAL?

No. 4-Pro-MET is not described in Shulgin's TiHKAL (1997). The book does include 4-HO-MET (entry #21), the active metabolite that 4-Pro-MET converts into. 4-Pro-MET was created decades after TiHKAL's publication.

Why was 4-Pro-MET created?

Market forces drove its creation: 4-HO-MET was NpSG-scheduled in Germany (2019) and 4-AcO-DMT was BtMG-listed (2022). 4-Pro-MET offered a legal, more stable prodrug of the popular 4-HO-MET that fell outside existing scheduling definitions due to its different ester structure.

What is 4-Pro-MET's PubChem CID?

4-Pro-MET's PubChem CID is 169222171. Its molecular formula is C16H22N2O2 with a molecular weight of 274.364 g/mol. The IUPAC name is [3-[2-[ethyl(methyl)amino]ethyl]-1H-indol-4-yl] propanoate.